South Korea–based biotech startup Galux has raised $29 million (KRW 42 billion) in its Series B funding round. The company uses AI technology to design protein-based medicines.
With this latest funding, Galux’s total capital raised has reached $47 million (KRW 68 billion) so far.
Galux’s Series B funding round included support from existing investors such as InterVest, DAYLI Partners, and PATHWAY Investment. The round also attracted new institutional investors, including Yuanta Investment, Korea Development Bank (KDB), SL Investment, NCORE Ventures, SneakPeek Investments, Korea Investment & Securities, and Mirae Asset Securities.
Earlier, in 2022, Galux raised $18 million (KRW 21 billion) in its Series A round. This funding helped the company improve its AI platform and strengthen its research and development capabilities.
Since then, Galux has achieved several important research and business milestones, leading to the successful closing of its Series B round. This reflects the company’s strong execution and continued growth
“Since our initial seed investment, Galux has consistently demonstrated strong technical depth and disciplined execution,” said Sang-gyun Kim, Ph.D, Executive Managing Director at InterVest. “The company’s capability to build a globally competitive AI platform for de novo protein design strengthens our conviction in its technology and its long-term potential to transform drug discovery.”
Galux has built an AI-powered protein design platform called GaluxDesign. It focuses on creating new antibodies from scratch, which is one of the hardest tasks in drug discovery. The platform has successfully created strong, high-quality antibodies for different medical targets. Tests also showed that the antibody structures designed by AI closely matched real lab results, proving the platform is both accurate and reliable.
Galux combines its advanced AI technology with fast feedback from its own laboratory, which helps improve the system quickly. Using this strong base, the company is now working on even more complex targets, such as GPCRs and ion channels, which are usually difficult to develop drugs for.
Using its technology, Galux is also growing its strategic partnerships. It is working with leading Korean pharmaceutical companies like Celltrion and LG Chem, and has recently partnered with Boehringer Ingelheim, supporting its expansion into global markets.
The new funding will be used to improve the AI platform, grow research and development facilities, and speed up early-stage testing of its own drug candidates. Through this, Galux aims to open up new treatment possibilities and tackle disease targets that were previously hard to address with traditional methods.
“Rapidly evolving AI technologies are driving a paradigm shift in drug discovery—from empirical discovery to rational drug design,” said Cha-ok Seok, CEO of Galux. “This funding will accelerate the development of next-generation AI that goes beyond binder design to incorporate functional activity and developability, enabling the creation of more robust and therapeutically viable molecules.”
Read More- CURAPOD raises INR 20 crore Pre-Series A round led by V3 Ventures
